Regeneron Pharmaceuticals, Inc. (REGN), 2024 Q4 earnings digest

from Earnings Report Digest · host ValueVerge

$REGN has released its Q4 2024 earnings, showing notable growth and strong performance across its key products like Dupixent, Libtayo, and EYLEA. Key stats indicate a 10% increase in total revenues to $3.8 billion and an earnings per share rise to $12.07, highlighting robust profitability. However, EYLEA is facing competitive pressure which could impact future growth.

Episode metadata supplied by the publisher feed · Published Feb 5, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Regeneron Pharmaceuticals, Inc. (REGN), 2024 Q4 earnings digest

0:00 1:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Earnings Report Digest?

This episode is 1 minute long.

When was this Earnings Report Digest episode published?

This episode was published on February 5, 2025.

Can I download this Earnings Report Digest episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!